Literature DB >> 9274473

Gut lavage IgG and interleukin 1 receptor antagonist:interleukin 1 beta ratio as markers of intestinal inflammation in children with inflammatory bowel disease.

R Troncone1, N Caputo, A Campanozzi, M Cucciardi, V Esposito, R Russo, B De Vizia, L Greco, S Cucchiara.   

Abstract

BACKGROUND: Whole gut lavage is currently used as preparation before radiological or endoscopic examination of the large bowel. AIM: To validate the gut lavage technique for the assessment of mucosal inflammation, by measuring intestinal IgG and interleukin 1 beta (IL-1 beta) in the fluid obtained. PATIENTS: Sixteen children with Crohn's disease (CD), 14 with ulcerative colitis (UC), and 22 age matched controls.
METHODS: Isotonic, non-absorbable polyethylene glycol based lavage solution was given orally or by nasogastric tube. Clear fluid was collected, filtered, and treated with protease inhibitors. IgG, IL-1 beta and IL-1-receptor antagonist (IL-1-ra) were measured by sandwich enzyme linked immunosorbent assay (ELISA).
RESULTS: In patients with UC and CD, IgG and IL-1 beta levels were significantly (p < 0.001) higher than in controls. A positive correlation (p < 0.05) was found with disease activity scores. IL-1-ra levels were not significantly different in UC and CD, when compared with controls, but the IL-1-ra:IL-1 beta ratio was significantly (p < 0.01) lower in patients with UC and CD, and negatively (p < 0.001) correlated with IgG levels in lavage fluid.
CONCLUSIONS: Gut lavage fluid IgG and IL-1 beta levels and IL-1-ra:IL-1 beta ratio may provide objective discrimination between active and inactive disease in children with inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9274473      PMCID: PMC1027229          DOI: 10.1136/gut.41.1.60

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  21 in total

1.  Appraisal of gut lavage in the study of intestinal humoral immunity.

Authors:  S O'Mahony; J R Barton; S Crichton; A Ferguson
Journal:  Gut       Date:  1990-12       Impact factor: 23.059

2.  Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor.

Authors:  C H Hannum; C J Wilcox; W P Arend; F G Joslin; D J Dripps; P L Heimdal; L G Armes; A Sommer; S P Eisenberg; R C Thompson
Journal:  Nature       Date:  1990-01-25       Impact factor: 49.962

3.  Enhanced production of interleukin 1-beta by mononuclear cells isolated from mucosa with active ulcerative colitis of Crohn's disease.

Authors:  Y R Mahida; K Wu; D P Jewell
Journal:  Gut       Date:  1989-06       Impact factor: 23.059

4.  Polyethylene glycol-electrolyte solution for intestinal clearance in children with refractory encopresis. A safe and effective therapeutic program.

Authors:  K B Ingebo; M B Heyman
Journal:  Am J Dis Child       Date:  1988-03

5.  Relationship of interleukin-1 receptor antagonist to mucosal inflammation in inflammatory bowel disease.

Authors:  J S Hyams; J E Fitzgerald; N Wyzga; R Muller; W R Treem; C J Justinich; D L Kreutzer
Journal:  J Pediatr Gastroenterol Nutr       Date:  1995-11       Impact factor: 2.839

6.  Immunohistochemical characterization of local immunoglobulin formation in Crohn's disease of the ileum.

Authors:  K Baklien; P Brandtzaeg
Journal:  Scand J Gastroenterol       Date:  1976       Impact factor: 2.423

7.  Interleukin 1 (IL-1) gene expression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis.

Authors:  F Cominelli; C C Nast; B D Clark; R Schindler; R Lierena; V E Eysselein; R C Thompson; C A Dinarello
Journal:  J Clin Invest       Date:  1990-09       Impact factor: 14.808

8.  A method of obtaining, processing, and analyzing human intestinal secretions for antibody content.

Authors:  M M Gaspari; P T Brennan; S M Solomon; C O Elson
Journal:  J Immunol Methods       Date:  1988-05-25       Impact factor: 2.303

9.  Use of Golytely in children and adolescents.

Authors:  V Tolia; S Fleming; R S Dubois
Journal:  J Pediatr Gastroenterol Nutr       Date:  1984-06       Impact factor: 2.839

10.  Role of interleukin 1 in inflammatory bowel disease--enhanced production during active disease.

Authors:  M Ligumsky; P L Simon; F Karmeli; D Rachmilewitz
Journal:  Gut       Date:  1990-06       Impact factor: 23.059

View more
  6 in total

1.  Intestinal inflammation in cystic fibrosis.

Authors:  R L Smyth; N M Croft; U O'Hea; T G Marshall; A Ferguson
Journal:  Arch Dis Child       Date:  2000-05       Impact factor: 3.791

2.  Distal proctocolitis and n-3 polyunsaturated fatty acids (n-3 PUFAs): the mucosal effect in situ.

Authors:  Y Z Almallah; S W Ewen; A El-Tahir; N A Mowat; P W Brunt; T S Sinclair; S D Heys; O Eremin
Journal:  J Clin Immunol       Date:  2000-01       Impact factor: 8.317

3.  Lidocaine inhibits secretion of IL-8 and IL-1beta and stimulates secretion of IL-1 receptor antagonist by epithelial cells.

Authors:  M Lahav; M Levite; L Bassani; A Lang; H Fidder; R Tal; S Bar-Meir; L Mayer; Y Chowers
Journal:  Clin Exp Immunol       Date:  2002-02       Impact factor: 4.330

4.  Gut mucosal secretion of interleukin 1beta and interleukin-8 predicts relapse in clinically inactive Crohn's disease.

Authors:  I D Arnott; H E Drummond; S Ghosh
Journal:  Dig Dis Sci       Date:  2001-02       Impact factor: 3.199

5.  Human colon carcinomas constitutively express and shed type II IL-1 receptor, an IL-1 antagonist.

Authors:  Andrew W Stadnyk; Moorix M W Yeung; Sen Rong Yan
Journal:  Dig Dis Sci       Date:  2003-09       Impact factor: 3.199

Review 6.  Rectal effluent as a research tool.

Authors:  Jana M Rocker; Jack A DiPalma; Lewis K Pannell
Journal:  Dig Dis Sci       Date:  2014-09-02       Impact factor: 3.199

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.